Severe Asthma Study – Rob Oliphant - Asthma Society of Canada

Robert Oliphant is the President and CEO of the Asthma Society of Canada.  Rob is the President of the Global Allergy and Asthma Patient Platform and serves on the Steering Committee of Better Care Faster and the Governing Council of the Health Charities Coalition of Canada and was on the Steering Committee for the National Lung Health Framework. In 2013 he was awarded the Queen’s Diamond Jubilee Medal by the Governor General of Canada in recognition of his contributions to Canada.  From 2008 to 2011, Rob served as Member of Parliament of Canada, representing the riding of Don Valley West in the House of Commons.  Rob received his Bachelor of Commerce from the University of Toronto. He has a Masters of Divinity from the Vancouver School of Theology, at the University of British Columbia, and a Doctorate from the Chicago Theological Seminary at the University of Chicago.

Download the Presentation: Closing Presentation – Rob Oliphant | Severe Asthma Study – Rob Oliphant

Health Impact of Air Quality – Michael Brauer - Asthma Society of Canada

Michael Brauer is a Professor in the School of Population and Public Health at The University of British Columbia. He also directs the Bridge Program – a strategic training program linking public health, engineering and policy. His research focuses on the assessment of exposure and health impacts of air pollution, with specific interest in transportation-related and biomass air pollution. He has participated in monitoring and epidemiological studies throughout the world and served on advisory committees to the World Health Organization, the US National Academy of Sciences, the Royal Society of Canada, the International Joint Commission and governments in North America and Asia. He is an Associate Editor of Environmental Health Perspectives.

Download the Presentation: Health Impact of Air Quality – Michael Brauer

Corticosteroids in the treatment of acute asthma

REVIEW ARTICLE

Year : 2014  |  Volume : 9  |  Issue : 4  |  Page : 187-192

Abdullah A Alangari

Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Date of Submission    09-Dec-2013

Date of Acceptance    10-Mar-2014

Date of Web Publication    4-Sep-2014

DOI: 10.4103/1817-1737.140120

Small airway dysfunction is associated to excessive bronchoconstriction in asthmatic patients

Research

Veronica Alfieri¹, Marina Aiello¹, Roberta Pisi¹, Panagiota Tzani¹, Elisa Mariani¹, Emilio Marangio¹, Dario Olivieri¹, Gabriele Nicolini² and Alfredo Chetta^1*

• *Corresponding author: Alfredo Chetta chetta@unipr.it

Author Affiliations

¹Clinical & Experimental Medicine Department, University of Parma, Padiglione Rasori, via G. Rasori 10, Parma, 43125, Italy

²Corporate Clinical Development, Chiesi Farmaceutici S.p.A, Parma, Italy

For all author emails, please log on.

Respiratory Research 2014, 15:86  doi:10.1186/s12931-014-0086-1

The electronic version of this article is the complete one and can be found online at:http://respiratory-research.com/content/15/1/86

Received:	1 April 2014
Accepted:	20 July 2014
Published:	27 August 2014

© 2014 Alfieri et al.; licensee BioMed Central Ltd. 

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Current evidence of epidermal barrier dysfunction and thymic stromal lymphopoietin in the atopic march

Eur Respir Rev. 2014 Sep;23(133):292-298.

Li M.

Japanese guideline for occupational allergic diseases 2014

REVIEW ARTICLE

doi:10.2332/allergolint.14-RAI-0771

Kunio Dobashi, Kazuo Akiyama, Atsushi Usami, Hiroo Yokozeki, Zenro Ikezawa, Naomi Tsurikisawa, Yoichi Nakamura, Kazuhiro Sato, Jiro Okumura, on behalf of Committee for Japanese Guideline for Diagnosis and Management of Occupational Allergic Diseases and Japanese Society of Allergology [About this authors]

Placebo Controlled Randomised Trial of Medical Therapy in Otitis Media with Effusion

Glenis Kathleen Scadding* , Allergy & Rhinology , University College London , United Kingdom

Yvonne Colette Darby , Allergy & Rhinology , Royal National TNE Hospital

Anna Jansz , Allergy & Rhinology , RNTNE Hospital, London

David Richards , Respiratory , *Glaxo Smith Kline, Stevenage.

Helen Tate , Statistics , MSD Hertford Rd, Hoddesdon, EN11 9BU

Simon Gane , ENT Surgery , University College London

Abstract

Objective
To explore rhinitis treatment, with and without autoinflation of the middle ear, as therapy for otitis media with effusion

Severe Asthma Phenotyping: The Applicability of Current Proposols in Daily Practice

Research Article

Volume 1 Issue 1 - 2014

Adile Berna Dursun1,2*, Ferda Oner Erkekol2 and Ozlem Kar Kurt2,3

1Department of Internal Medicine, Division of Immunology and Allergic Diseases, Recep Tayyip Erdogan University School of Medicine, Turkey
2Divison of Immunology and Allergic Diseases, Ataturk Chest Disease and Thoracic Surgery Trainig and Research Hospital, Turkey
3Department of Respiratory Medicine, Izzet Baysal University School of Medicine, Turkey

Received: August 12, 2014 | Published: August 21, 2014

*Corresponding author: Adile Berna Dursun, Department of Internal Medicine, Division of Immunology and Allergic Diseases, Recep Tayyip Erdogan University School of Medicine, Rize, Turkey, Tel: 905325874868; Email: @

Citation: Dursun AB, Erkekol FO, Kurt OK (2014) Severe Asthma Phenotyping: The Applicability of Current Proposols in Daily Practice. J Lung Pulm Respir Res 1(1): 00003. http://dx.doi.org/10.15406/jlprr.2014.01.00003

  

Abstract

Background: Severe asthma (SA) is also need to be phenotyping. We aimed to demonstrate the applicability of current definition and classification proposals in daily practice.
Methods: SA patients, according to WHO definition of treatment resistant SA, were enrolled from the allergy clinic. The SARP algorith define and WHO proposal were applied to the subjects independently by asthma experts. Demographic and clinical characteristics of the subjects were used for the comparison.
Results: Ninety-five (F/M: 68/27) patients with a mean age of 45.97± 9.44 years (range25-71) were enrolled. The patients were grouped as controlled treatment-resistant SA (56%) and uncontrolled treatment resistant SA group (44%). There was no statistically significant difference between the groups but aspirin hypersensitivity. 49% of patients was classified as exacerbators, 26% as fixed airway obstruction group and 23% as undefined (other 2%). Age and mold sensitivity was higher; FEV1/FVC and FEF25-75 were lower in exacerbation-prone SA. More than half of the patients were define clustered at 4 and 5 according to SARP proposol. Patients with fixed obstruction were only in the clusters 4 and 5.
Conclusion: Current phenotyping proposols failed to cover all SA patients. Thus, there is still need further investigations in order to explore validity and applicability of the phenotyping of SA.

Keywords: Adult asthma; Severe asthma; Phenotype; Cluster analysis; Refractory asthma; Difficult-to-treat asthma

PDF   |   Full Text